Ernexa Therapeutics (ERNA) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Ernexa Therapeutics (ERNA) is Moderate Underperform.

The composite score behind that read is -0.36, weighing +0.00 of bullish evidence against -0.52 bearish.

Ernexa Therapeutics last closed at $2.21, -7.92% on the session.

Against the IVW growth benchmark the position is -7.49% over the forecast window.

The read is built from 11 underlying insights — 0 bullish and 11 bearish.

Agreement across those insights is 100%.

21 graded predictions for ERNA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Ernexa Therapeutics in the 3rd percentile on return on equity, where 100 is best.

Ernexa Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $3.92M.

StockMap tracks Ernexa Therapeutics as the 378th largest of the 386 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 307 Neutral, 66 Moderate Underperform and 13 Moderate Outperform.

On that composite Ernexa Therapeutics ranks 378th of 386 in the group, against a group median of -0.08.